Physician profile
Robert R Blanco
NPI 1487638805
$2,856.85
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $17.27 · 2021: $600 · 2022: $1,241 · 2023: $655 · 2024: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventric Diagnostics, INC. | $660.60 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $420.18 | 2020-2024 | |
| Amgen INC. | $346.51 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.62 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $145.42 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $145.14 | 2021-2024 | Xarelto |
| Endologix LLC | $132.27 | 2022 | |
| Pfizer INC. | $117.54 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $109.35 | 2021-2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.78 | 2021-2023 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $83.69 | 2019-2023 | Brilinta, Farxiga |
| Scpharmaceuticals INC. | $61.53 | 2023 | |
| Alnylam Pharmaceuticals INC. | $48.24 | 2021-2023 | Onpattro |
| Abbott Laboratories | $45.98 | 2022-2023 | Cardiomems |
| Actelion Pharmaceuticals US, INC. | $45.82 | 2024 | Uptravi, Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $31.91 | 2022 | |
| Boston Scientific Corporation | $28.58 | 2023 | Watchman Access System |
| Edwards Lifesciences Corporation | $18.87 | 2022 | |
| Amarin Pharma, INC. | $17.80 | 2019 | |
| Astellas Pharma US INC | $16.61 | 2019 | |
| Lantheus Medical Imaging, INC. | $15.95 | 2019 | |
| Esperion Therapeutics, INC. | $14.21 | 2024 | Nexletol |
| Masimo Corporation | $13.25 | 2023 | Set and Rainbow Set |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.